CStone Pharmaceuticals (the Company) announced that the Stock Exchange of Hong Kong has confirmed the qualification of Joint Company Secretary Ms. Ni under Rule 3.28 of the Listing Rules, effective upon the expiry of a waiver on January 17, 2026. As a result, Ms. Yung resigned as a Joint Company Secretary on February 6, 2026, and Ms. Ni continues as the sole company secretary.

The Company also noted that Ms. Yung resigned as an authorized representative in tandem with her departure from the Joint Company Secretary role. Ms. Ni has assumed the authorized representative position effective February 6, 2026, joining Dr. Yang in that capacity. Meanwhile, Ms. Yung remains as the process agent in Hong Kong. The Company’s board expressed gratitude to Ms. Yung for her contributions during her tenure.